Astellas Business in Russia

Eiji Nakane Corporate Planning Astellas Pharma Inc.



Corporate Profile



Philosophy: Leading Light for Life

"Contribute toward improving the health of people around the world through the provision of innovative & reliable pharmaceutical products."

Business Description: Ethical pharmaceuticals (deployed globally)

Japan's 2nd largest (market cap*) pharmaceutical company

Top 20 overall in the global market

17,085 employees worldwide*



Founded in 1894

Leader in Transplantation / Immunology, Nuclear Cardiology, Infectious Disease & Dermatology





Founded in 1923


Leader in Urology and Gastroenterology

*As of March 31, 2012

Steady Global Expansion Across 4 Regions



Consolidated net sales (FY2011): 969.3 billion yen



- Group HQ/Regional HQ
- Sales Affiliate/Promotion Base in Europe

Astellas - Our Business Model in Global




Establish a competitive edge as a Global Category Leader (GCL)

Urology
Oncology

Immunology
& Infectious
Diseases
> Neuroscience
> DM Complications
& Kidney Diseases
etc.

Our Presence in Emerging Market – Russia





Astellas Russia Snapshot



- History:
 - 1991 With the acquisition of Gist Brocades, Representative Office was established
 - 1994 The name was changed to Yamanouchi
 - 2005 The name was changed to Astellas by the merger
- FY2011 Sales in Russia: approx. €200 MM
- Wider product portfolio:

Therapeutic Area	Product
Anti-biotics	Flemoxin, Josamycin, Mycamine®
Gastro-enterology	De-Nol®
Urology	Tamsulosin – Omnic®, Tocas®, Vesicare®
Dermatology	Protopic® etc.
Transplant/Immunology	Tacrolimus – Prograf®/Advagraf®
Oncology	Bendamustine, Eligard®

What we look forward to in the future -Russian pharma market



Issues to continue dialogue

- Government policies in healthcare:
 Future outlook of 'Strategy 2020'
- Clinical trials procedure
- Process of obtaining registration, price and reimbursement (DLO and 7D)
- GMP standards and manufacturing

Issues Japanese pharmas are facing

- Uptake of Innovation
- Price sensitivity
- Further regulation by government to restrict foreign market players and to enhance the following:
 - ✓ Local production
 - ✓ Local development